Biomarker Testing Services Market Size, Share & Trends Report

Biomarker Testing Services Market (2025 - 2030) Size, Share & Trends Analysis Report By Service (Biomarker Assay Development & Validation, Flow Cytometry), By Application (Oncology, Drug Discovery & Development), By Type, By End-use,By Region, And Segment Forecasts

Market Segmentation

Biomarker Testing Service Outlook (Revenue in USD Million, 2018 - 2030)
- Biomarker Assay Development & Validation
- Flow Cytometry
- Others
Biomarker Testing Services Application Outlook (Revenue in USD Million, 2018 - 2030)
- Oncology
- Drug Discovery & Development
- Others
Biomarker Testing Services Type Outlook (Revenue in USD Million, 2018 - 2030)
- Molecular Biomarkers
- Cellular Biomarkers
Biomarker Testing Services End Use Outlook (Revenue in USD Million, 2018 - 2030)
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- CROs
Biomarker Testing Services Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - North America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - North America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
    - North America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - U.S.
    - U.S. Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - U.S. Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - U.S. Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - U.S. End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Canada
    - Canada Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Canada Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Canada Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Canada End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Mexico
    - Mexico Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Mexico Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Mexico Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Mexico End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
- Europe
  - Europe Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - Europe Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - Europe Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
  - Europe End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - UK
    - UK Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - UK Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - UK Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - UK End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Germany
    - Germany Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Germany Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Germany Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Germany End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - France
    - France Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - France Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - France Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - France End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Italy
    - Italy Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Italy Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Italy Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Italy End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Spain
    - Spain Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Spain Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Spain Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Spain End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Denmark
    - Denmark Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Denmark Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Denmark Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Denmark End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Sweden
    - Sweden Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Sweden Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Sweden Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Sweden End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Norway
    - Norway Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Norway Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Norway Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Norway End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
- Asia Pacific
  - Asia Pacific Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - Asia Pacific Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - Asia Pacific Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
  - Asia Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - Japan
    - Japan Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Japan Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Japan Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Japan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - China
    - China Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - China Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - China Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - China End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - India
    - India Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - India Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - India Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - India End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - South Korea
    - South Korea Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - South Korea Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - South Korea Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - South Korea End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Australia
    - Australia Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Australia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Australia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Australia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Thailand
    - Thailand Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Thailand Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Thailand Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Thailand End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Indonesia
    - Indonesia Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Indonesia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Indonesia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Indonesia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Malaysia
    - Malaysia Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Malaysia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Malaysia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Malaysia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Singapore
    - Singapore Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Singapore Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Singapore Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Singapore End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Taiwan
    - Taiwan Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Taiwan Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Taiwan Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Taiwan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
- Latin America
  - Latin America Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - Latin America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - Latin America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
  - Latin America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - Brazil
    - Brazil Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Brazil Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Brazil Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Brazil End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Argentina
    - Argentina Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Argentina Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Argentina Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Argentina End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
- Middle East and Africa
  - Middle East and Africa Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - Middle East and Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - Middle East and Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
  - Middle East and Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - South Africa
    - South Africa Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - South Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - South Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - South Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Saudi Arabia
    - Saudi Arabia Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Saudi Arabia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Saudi Arabia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Saudi Arabia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - UAE
    - UAE Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - UAE Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - UAE Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - UAE End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Kuwait
    - Kuwait Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Kuwait Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Kuwait Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Kuwait End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Israel
    - Israel Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Israel Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Israel Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Israel End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments